News Sentiment

ATHE sentiment intelligence

Alterity Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.98 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-8.3% over one week, +2.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Alterity Therapeutics CEO to Engage U.S. Investors at BTIG Biotechnology Conference 2026

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -8.3% Price reacting lower
Trend fit Trend active 2.0% over four weeks
Fair value 61.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 34
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 9
TradingView 7
Kalkine 7
GlobeNewswire 5
Moomoo 4
Kalkine Media 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 14
Analyst action 2
Balance sheet 2
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Market source Direct company coverage

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that its CEO, Dr. David Stamler, will participate in the virtual BTIG Biotechnology Conference 2026 from July 28-29, 2026. Dr. Stamler will conduct one-on-one meetings with investors to discuss the company's progress in dev

Tone
Positive 65/100
Event
Market update
Published
21 Jul 2026 11:09
Source
Market source
Stock Titan Direct company coverage

Alterity CEO to Host 1-on-1 U.S. Investor Meetings

Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) announced that CEO David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026, scheduled for July 28-29, 2026. Dr. Stamler will host one-on-one meetings with U.S. investors to discuss the company's progre

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 11:09
Source
Stock Titan
Stock Titan Direct company coverage

Alterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech event

Alterity Therapeutics will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. CEO David Stamler, M.D., will host one-on-one meetings with investors to discuss the company's focus on disease-modifying therapies for neurodegenerative diseases, partic

Tone
Positive 66/100
Event
Market update
Published
21 Jul 2026 10:09
Source
Stock Titan
Stock Titan Direct company coverage

[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)

ALTERITY THERAPEUTICS LTD filed a Form 6-K Current Report with the SEC on July 21, 2026. This foreign private issuer report indicates the company's compliance with SEC regulations and is incorporated by reference into several of its registration statements. The report includes an

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 10:09
Source
Stock Titan
TradingView Direct company coverage

Alterity Therapeutics Ltd Warrant 2023 - 31.08.26 On Alterity Financial Disclosures & Filings

This article provides access to financial disclosures and filings for Alterity Therapeutics Ltd (ATHo) Warrant 2023 - 31.08.26. It lists various corporate documents, including earnings reports, corporate presentations, and study updates from 2023 to 2026, highlighting the develop

Tone
Positive 74/100
Event
Earnings
Published
21 Jul 2026 09:09
Source
TradingView
Kalkine Direct company coverage

Alterity Therapeutics CEO to Present at Virtual BTIG Biotechnology Conference 2026

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a clinical-stage biotechnology company, announced that CEO Dr. David Stamler will present at the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. The company will conduct one-on-one investor meetings to discuss its le

Tone
Positive 73/100
Event
Market update
Published
21 Jul 2026 07:09
Source
Kalkine
Kalkine Media Direct company coverage

Alterity Therapeutics CEO to Speak at Virtual BTIG Biotechnology Conference 2026 on July 28-29

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a clinical-stage biotechnology company, announced that CEO Dr. David Stamler will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29. The company plans to hold one-on-one investor meetings at the conference

Tone
Positive 71/100
Event
Market update
Published
21 Jul 2026 07:09
Source
Kalkine Media
Kalkine Direct company coverage

Alterity Therapeutics Converts 40,209 Options Into Ordinary Shares at 50 Cents Each

Alterity Therapeutics (ASX: ATH) has converted 40,209 options into ordinary fully paid shares at an exercise price of AUD 0.50 per share, generating AUD 20,104.50. This conversion increases the company's quoted ordinary share capital to 217,629,367 shares. The company maintains a

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 03:03
Source
Kalkine
Kalkine Media Direct company coverage

Alterity Therapeutics Executes Conversion of 40,209 Options into Ordinary Shares at AUD 0.50 Each

Alterity Therapeutics (ATH) has converted 40,209 options into ordinary fully paid shares, issued at AUD 0.50 each on July 21, 2026. This conversion increases the company's total quoted ordinary share capital to 217,629,367 shares. The company still retains a significant number of

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 03:03
Source
Kalkine Media
Kalkine Direct company coverage

Alterity Therapeutics (ASX:ATH) Declines Nearly 9.5% — What Is Behind the Neurodegeneration Drug Developer’s Fall?

Alterity Therapeutics (ASX:ATH) experienced a nearly 9.5% decline in its share price. The company is a neurodegeneration drug developer, and its stock performance is closely linked to clinical trial outcomes and broader sector sentiment. Investors are advised to monitor the compa

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 05:41
Source
Kalkine
Kalkine Direct company coverage

Alterity Therapeutics (ASX:ATH) Falls as Biotech Volatility Returns to the ASX

Alterity Therapeutics (ASX:ATH), a clinical-stage biotechnology company focused on neurodegenerative diseases, saw its share price fall, highlighting the inherent volatility of such stocks. The company is developing ATH434 for Multiple System Atrophy and has reported positive reg

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 13:09
Source
Kalkine
Moomoo Direct company coverage

Alterity Therapeutics Receives AU$4 Million Tax Refund From Australian Government

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received an AU$4 million cash refund under the Australian government's R&D tax incentive program. This refund is related to eligible research and development expenditures incurred during the 2023-2024 financial year. The funds wi

Tone
Positive 76/100
Event
Balance sheet
Published
09 Jul 2026 11:17
Source
Moomoo
Stock Titan Direct company coverage

[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K

Alterity Therapeutics Limited (ATHE) filed a Form 6-K Current Report with the SEC on July 9, 2026, confirming its status as a foreign private issuer. This filing indicates that the company will continue to file annual reports under Form 20-F and confirms the incorporation by refe

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 11:09
Source
Stock Titan
Stock Titan Direct company coverage

Alterity Therapeutics (NASDAQ: ATHE) receives A$3.98m R&D tax refund

Alterity Therapeutics has received an A$3.98 million R&D tax refund for the 2025 financial year from the Australian Government, including interest. This non-dilutive funding will support the company's ongoing clinical programs, particularly the development of its lead candidate A

Tone
Positive 67/100
Event
Market update
Published
09 Jul 2026 10:09
Source
Stock Titan
Kalkine Direct company coverage

Alterity Therapeutics Announces Quotation of New Securities Following Option Conversion

Alterity Therapeutics (ASX: ATH) has announced the quotation of 76,191 new ordinary fully paid shares on the ASX following the conversion of options with an issue price of AUD 0.50 per share. This strategic move increases the company's total shares to 217,589,158 and aims to enha

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 02:09
Source
Kalkine
Proactive financial news Direct company coverage

Alterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathway

Alterity Therapeutics has secured FDA confirmation for a registrational pathway for its lead drug candidate, ATH434, for Multiple System Atrophy (MSA). The FDA agreed to a single pivotal Phase 3 trial supported by confirmatory evidence, clarifying the clinical development strateg

Tone
Positive 74/100
Event
Market update
Published
08 Jul 2026 00:11
Source
Proactive financial news
Moomoo Direct company coverage

Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy

Alterity Therapeutics announced that the FDA has endorsed its Phase 3 clinical trial design for ATH434, a treatment for Multiple System Atrophy (MSA). This agreement marks a significant step forward for the therapy which aims to address the neurodegenerative disorder. The FDA's s

Tone
Positive 82/100
Event
Market update
Published
07 Jul 2026 14:40
Source
Moomoo
grafa.com Direct company coverage

Alterity Therapeutics aligns with FDA on Phase 3 neurology drug path

Alterity Therapeutics has received official FDA meeting minutes, confirming the regulatory pathway for its ATH434 Phase 3 Multiple System Atrophy drug trial. The FDA has agreed that a single pivotal efficacy study, supported by existing Phase 2 findings, will be sufficient for a

Tone
Positive 92/100
Event
Regulatory and legal
Published
07 Jul 2026 14:14
Source
grafa.com
Stock Titan Direct company coverage

FDA backs single Phase 3 trial for Alterity’s MSA drug ATH434

Alterity Therapeutics has received official FDA End-of-Phase 2 meeting minutes for its drug ATH434, confirming a clear registrational pathway for Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, along with existing Phase 2 data as confirmatory ev

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 11:05
Source
Stock Titan
Stock Titan Direct company coverage

FDA outlines single Phase 3 trial plan for Alterity (NASDAQ: ATHE) ATH434

Alterity Therapeutics announced that the FDA has confirmed a single pivotal Phase 3 trial, supported by confirmatory evidence, is sufficient for potential approval of ATH434 for Multiple System Atrophy (MSA). The Phase 3 study, expected to enroll approximately 200 patients, will

Tone
Positive 72/100
Event
Regulatory and legal
Published
07 Jul 2026 10:10
Source
Stock Titan
Moomoo Direct company coverage

Alterity Therapeutics Says US FDA Meeting Minutes Confirm Key Elements of Phase 3 MSA Treatment Candidate Program; Shares Fall 4%

Alterity Therapeutics announced that minutes from its recent meeting with the U.S. FDA confirmed the key elements of its Phase 3 clinical program for ATH434, a treatment candidate for Multiple System Atrophy (MSA). The FDA agreed on the primary endpoint, patient population, and s

Tone
Negative 28/100
Event
Market update
Published
06 Jul 2026 02:39
Source
Moomoo
TradingView Direct company coverage

Alterity Therapeutics Ltd Warrant 2025-26.02.27 on Alterity Thera Financial Disclosures & Filings

This article provides a list of financial disclosures and filings for Alterity Therapeutics Ltd Warrant 2025-26.02.27 (ATHOA) on the Australian Securities Exchange. The documents span from 2023 to 2026, primarily focusing on earnings reports, corporate presentations, and study up

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 22:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Alterity Therapeutics Ltd. – ASX:ATH

The article focuses on the "Price to earnings forward" financial metric for Alterity Therapeutics Ltd. (ASX:ATH). It indicates that the market regarding this particular financial data is currently closed with no trades. The content is primarily a data placeholder within a financi

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 07:39
Source
TradingView
Moomoo Direct company coverage

Alterity Therapeutics Ltd (ATH) News Flow

This article states that it provides a news flow for Alterity Therapeutics Ltd (ATH). However, the content provided is just the word "Document," indicating that the actual news flow information is missing or not provided in the input.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:40
Source
Moomoo